Key Takeaways
- Canada’s point-of-care diagnostics market is growing at 14% annually and is projected to reach $800 million by 2028.
- Post-pandemic investment in decentralized testing infrastructure, combined with provincial primary care reform, is accelerating POC adoption beyond emergency departments.
- Canadian companies including PocketDiagnostics, Biozone Labs, and CanTest Medical are competing for share against US giants Abbott, bioMérieux, and Roche Diagnostics.
- Health Canada’s IVDD (In Vitro Diagnostic Device) framework requires Class III approval for high-complexity POC tests a regulatory standard that is both a barrier and a moat for approved products.
Before March 2020, point-of-care diagnostics were a niche conversation in Canadian health policy interesting technology, limited adoption, moderate growth. The pandemic changed everything. The deployment of rapid antigen tests to tens of millions of Canadians created a population-scale familiarity with POC testing that did not exist before, and the infrastructure investment made by governments and healthcare systems to support COVID-era decentralized testing created a foundation that is now being repurposed for a much broader array of diagnostic applications. The Canadian POC diagnostics market is projected to reach $800 million by 2028, growing at 14% annually and Canadian companies are working hard to capture a piece of a market long dominated by international giants.
The Market Segments
The Canadian POC diagnostics market divides into three primary segments. Infectious disease testing including influenza, RSV, strep, COVID, and sexually transmitted infection panels is the largest and most established segment, representing approximately 42% of the market. Cardiac biomarker testing troponin, BNP, D-dimer accounts for roughly 28% and is the fastest-growing segment, driven by both clinical utility and the push to decentralize emergency department care. Metabolic and endocrine testing HbA1c, blood glucose, thyroid function represents approximately 22% of the market, with the balance distributed across coagulation monitoring, drug testing, and specialty panels.
The deployment settings for POC diagnostics in Canada are also diversifying beyond the traditional emergency department and intensive care unit context. Primary care clinics, pharmacy-embedded health clinics, remote and First Nations community health centres, occupational health facilities, and long-term care homes are all expanding their POC testing programs each with distinct procurement processes, regulatory requirements, and reimbursement frameworks.
| Market Segment | 2026 Canadian Revenue (est.) | Growth Rate | Key Canadian Players | Key International Competitors |
|---|---|---|---|---|
| Infectious Disease POC | $248M | +11% YoY | PocketDiagnostics, CanTest Medical | Abbott, bioMérieux, Roche |
| Cardiac Biomarker POC | $165M | +19% YoY | AlignaTech (ATH.V), BioHeartX | Abbott (i-STAT), Radiometer, Siemens |
| Metabolic/Endocrine POC | $130M | +12% YoY | Biozone Labs | Roche (CoaguChek), Abbott (Afinion) |
| Coagulation Monitoring | $68M | +8% YoY | Limited Canadian presence | Roche, Werfen, Stago |
| Specialty & Other | $47M | +16% YoY | Multiple early-stage | Various |
Health Canada’s IVDD Regulatory Framework
Health Canada regulates POC diagnostic tests as In Vitro Diagnostic Devices (IVDDs) under the Medical Devices Regulations. The classification ranges from Class I (low risk, general laboratory reagents) to Class IV (high risk, tests for life-threatening conditions or where an error would have serious consequences). Most POC tests of clinical significance fall into Class III or Class IV, requiring premarket licensing submissions that demonstrate safety, effectiveness, and quality manufacturing.
The regulatory pathway is both a barrier to entry it takes 12-24 months and significant investment to obtain a Class III IVDD licence and a competitive moat once achieved. Companies with Health Canada-licensed POC diagnostics enjoy a regulatory advantage over products that have not completed the licensing process, and Canadian hospital procurement teams require Health Canada licensing for institutional purchasing decisions. For Canadian companies, the IVDD framework creates a home-market advantage that can be leveraged into export positioning, as many international regulatory bodies recognize Health Canada licensing as evidence of quality.
Canadian Companies: Building in the Shadow of Giants
PocketDiagnostics, based in Waterloo, Ontario, has developed a multiplexed respiratory pathogen panel for the point-of-care setting that simultaneously tests for influenza A/B, RSV, COVID-19, and Mycoplasma pneumoniae from a single nasopharyngeal swab in 18 minutes. The company received its Health Canada Class III IVDD licence in 2025 and has begun supplying Ontario hospital emergency departments and pharmacies under a provincial emergency preparedness supply agreement.
Biozone Labs, based in Calgary, focuses on the metabolic testing segment, offering a HbA1c and lipid panel POC system designed for primary care and pharmacy deployment. The company has supply agreements with 340 Alberta pharmacies and is expanding into BC and Ontario. CanTest Medical, headquartered in Halifax, has developed a sexually transmitted infection panel for the pharmacy and community health centre setting addressing an underserved diagnostic need in Canadian primary care.
The Pharmacy Channel: A Structural Shift
One of the most significant structural changes in Canadian POC diagnostics is the expansion of pharmacy-based testing. Provinces have progressively expanded pharmacist scope of practice, and pharmacies with POC testing capabilities are now authorized to bill provincial insurance plans for certain diagnostic services in Ontario, Alberta, and British Columbia. Shoppers Drug Mart’s HealthClinic network, Rexall’s pharmacy clinics, and independent pharmacy chains are all investing in POC diagnostic infrastructure to support expanded clinical service offerings creating a distribution channel for POC diagnostics that did not meaningfully exist five years ago.
The Bottom Line
Canada’s POC diagnostics market is entering a period of structural expansion that extends well beyond the pandemic-era testing surge. The combination of provincial primary care reform, pharmacy scope expansion, rural health equity imperatives, and an evidence base that continues to strengthen for POC testing across multiple clinical applications creates a durable growth backdrop for the next five years. Canadian companies face the genuine challenge of competing against much larger international players with established distribution networks and global brand recognition but the IVDD regulatory framework, Canadian-specific clinical validation requirements, and government procurement preferences for domestic suppliers create real competitive opportunities for companies that execute well on both the regulatory and commercial fronts.